List of Excipients in Branded Drug ACETAMINOPHEN AND IBUPROFEN BACK PAIN

Generic Drugs Containing ACETAMINOPHEN AND IBUPROFEN BACK PAIN

Company	Ingredient	NDC	Excipient
Aurohealth LLC	acetaminophen and ibuprofen	58602-895	FERRIC OXIDE YELLOW
Aurohealth LLC	acetaminophen and ibuprofen	58602-895	HYPROMELLOSE 2910
Aurohealth LLC	acetaminophen and ibuprofen	58602-895	LACTOSE MONOHYDRATE
Aurohealth LLC	acetaminophen and ibuprofen	58602-895	PALMITOSTEARIC ACID
Aurohealth LLC	acetaminophen and ibuprofen	58602-895	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in ACETAMINOPHEN AND IBUPROFEN BACK PAIN?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	FERRIC OXIDE RED

Acetaminophen and Ibuprofen for Back Pain: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

The acetaminophen/ibuprofen back-pain category is an OTC fixed-dose analgesic segment built around two generic active ingredients. The leading U.S. reference product, Advil Dual Action, combines acetaminophen 250 mg with ibuprofen 125 mg per caplet and carries labeling for minor aches and pains, including backache.[1] The active ingredients have limited standalone patent value. Commercial differentiation is more likely to come from excipient engineering, dose presentation, stability, packaging, brand protection, and retail execution.

What product is marketed as acetaminophen and ibuprofen for back pain?

The relevant product is an oral fixed-dose combination of acetaminophen and ibuprofen, not a separate active ingredient called "acetaminophen and ibuprofen back pain." Advil Dual Action is the principal U.S. branded example.

Attribute	Commercial profile
Active ingredients	Acetaminophen and ibuprofen
Representative strength	Acetaminophen 250 mg plus ibuprofen 125 mg per caplet
Dosage form	Immediate-release coated oral caplet
Primary OTC use	Temporary relief of minor aches and pains
Back-pain positioning	Backache and muscle ache within the OTC analgesic labeling framework
U.S. regulatory route	OTC monograph framework and/or product-specific FDA approval, depending on product
Main commercial owner	Haleon for Advil-branded consumer products
Generic active-ingredient status	Long-established and widely available
Main differentiation levers	Convenience, tolerability, onset, packaging, brand, price, and formulation

The combination uses different pharmacologic mechanisms. Acetaminophen provides analgesic and antipyretic activity, while ibuprofen is a nonsteroidal anti-inflammatory drug. A fixed-dose product can offer broader consumer positioning than either ingredient alone, but the label must control duplicate use and total daily exposure.

What excipients are used in acetaminophen and ibuprofen caplets?

Public product labeling identifies inactive ingredients, but manufacturers can change excipients, suppliers, grades, and processing conditions without changing the active ingredient claim. A representative immediate-release caplet may use the following excipient classes:

Excipient function	Typical candidates	Commercial purpose
Diluent	Microcrystalline cellulose, pregelatinized starch, lactose where compatible	Controls tablet mass and improves compressibility
Binder	Povidone, starch, hydroxypropyl cellulose	Supports granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes rapid tablet breakup
Lubricant	Stearic acid, magnesium stearate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves swallowability, appearance, and product identification
Surfactant or wetting aid	Sodium lauryl sulfate or other approved surfactant	Supports wetting and dissolution
Moisture barrier	Polymer coating, high-barrier bottle, blister laminate	Protects acetaminophen and ibuprofen from environmental stress
Taste and odor control	Film coating, capsule shell, flavor system for liquids	Reduces bitterness and improves consumer acceptance

The reference product’s exact excipient system should be taken from its current FDA label and manufacturer documentation. A competing product can use a different formulation while preserving the same active-ingredient amounts and OTC claims.[1]

Which excipients are most important for dissolution?

Rapid and reproducible dissolution is the principal technical objective for an immediate-release combination. The formulation has to release both actives despite their different physicochemical properties and different dose levels.

Key design variables include:

1. Particle size and surface area of each active.
2. Granulation method and granule porosity.
3. Disintegrant type and concentration.
4. Lubrication time and lubricant concentration.
5. Surfactant selection.
6. Compression force.
7. Coating weight and film permeability.
8. Dissolution performance across relevant pH conditions.

A formulation that releases acetaminophen rapidly but delays ibuprofen may produce an uneven onset profile. A formulation that disintegrates too aggressively can create friability, capping, or poor packaging performance.

How should excipients address ibuprofen’s formulation challenges?

Ibuprofen has limited water solubility relative to acetaminophen and can create dissolution constraints in conventional tablets. Excipient opportunities include:

• Wetting agents to improve water penetration.
• Micronized ibuprofen to increase surface area.
• Solid-dispersion or amorphous approaches where justified by stability data.
• Hydrophilic polymers to improve dissolution.
• Effervescent systems for rapid dispersion.
• Liquid-filled softgels for a different release and swallowability profile.
• Bilayer or multilayer tablets to separately optimize each active.

The commercial value of these approaches depends on measurable benefits. A formulation patent is more defensible when it links a specific excipient ratio or manufacturing process to an unexpected dissolution, stability, pharmacokinetic, or consumer-use result.

What formulations are protected by acetaminophen and ibuprofen patents?

The active ingredients themselves are off-patent. Potentially protectable subject matter lies in the combination and its delivery system.

Fixed-dose immediate-release tablets

A conventional 250 mg/125 mg caplet has a relatively weak patent profile if it relies on known active ingredients, standard excipients, and routine tablet manufacturing. A patent application based only on combining two known analgesics for back pain would face substantial obviousness risk.

Potential claim categories include:

• Specific acetaminophen-to-ibuprofen ratios.
• Defined dissolution windows for both actives.
• Bilayer or multilayer structures.
• Separate granules for each active.
• Particle-size distributions.
• Stabilized amorphous ibuprofen.
• Low-moisture manufacturing processes.
• Reduced tablet size at equivalent dose.
• Improved stability under accelerated conditions.
• Taste-masked liquid or chewable products.
• Packaging that limits moisture and preserves shelf life.

Liquid-filled capsules and softgels

Softgels can create a stronger differentiation path because they allow ibuprofen to be solubilized or dispersed in a liquid vehicle while acetaminophen is incorporated in a separate phase or suspension. Development risks include:

• Acetaminophen solubility and precipitation.
• Shell compatibility.
• Fill-volume constraints.
• Long-term leakage.
• Cross-migration between actives and vehicle.
• Oxidative and moisture stability.
• Larger unit size at the same dose.

A softgel is commercially attractive for consumers who associate liquid-filled capsules with rapid action, but that consumer perception must be supported by dissolution or clinical data before making an onset claim.

Bilayer tablets

A bilayer tablet can separate the actives physically and allow different excipient systems for each layer. It may support:

• Faster release from an acetaminophen layer.
• Enhanced ibuprofen dissolution from a wetting-agent layer.
• Reduced interaction during storage.
• A smaller tablet than two separate products.
• A differentiated manufacturing and patent position.

The principal manufacturing challenge is interfacial strength. Weak bonding between layers can cause delamination, capping, or dose nonuniformity.

Extended-release products

Extended-release acetaminophen/ibuprofen products could target longer-duration back pain, but they carry higher regulatory and clinical risk. A modified-release formulation would require clear control of:

• Release profiles for both active ingredients.
• Dose dumping.
• Food effects.
• Pharmacokinetic equivalence.
• Safety exposure over longer intervals.
• Appropriate labeling for repeated use.

The commercial opportunity is meaningful, but an extended-release claim cannot be inferred from a conventional OTC combination product.

When do acetaminophen and ibuprofen lose exclusivity?

The active ingredients have already lost meaningful U.S. exclusivity. Generic acetaminophen and ibuprofen products are widely available, and the basic pharmacologic combination is not a protected innovation.

Exclusivity element	Status
Acetaminophen composition of matter	Expired
Ibuprofen composition of matter	Expired
Basic analgesic use	Broadly established and not a strong exclusivity platform
Conventional tablet combination	Vulnerable to design-around and routine generic competition
Branded product name	Trademark protection, separate from drug patent protection
Specific formulation	Potentially patentable if technically novel and non-obvious
Manufacturing process	Potential patent or trade-secret protection
Packaging and dosing system	Potential design, utility, or trade-dress protection

The key commercial distinction is between a branded product and a protected drug technology. A brand can maintain share after patent expiry through recognition, shelf placement, advertising, and consumer trust. It cannot prevent a legally compliant generic from marketing the same active ingredients solely through the brand’s formulation history.

What is the Orange Book status of acetaminophen and ibuprofen products?

Orange Book analysis must be conducted at the product level. FDA’s Orange Book identifies approved drug products and certain patent and exclusivity information, but it does not function as a complete registry of every patent relevant to an OTC analgesic category.[2]

For OTC products, the practical barriers are often different from those for a new prescription drug:

• OTC monograph products generally rely on a standardized regulatory framework.
• A monograph-compliant competitor may not need to reproduce a branded product’s proprietary formulation.
• Formulation patents may be listed only if the relevant product is approved under an NDA and the patent meets FDA listing requirements.
• Trademarks, trade dress, advertising claims, and distribution agreements may matter more than Orange Book patents.

A generic or private-label entrant should review the current Orange Book, FDA-approved labeling, applicable OTC monograph provisions, and any publicly available patent litigation before launch.[2,3]

How strong is the patent estate for acetaminophen and ibuprofen back pain products?

The patent estate is generally weak for a standard immediate-release caplet and stronger for engineered delivery systems.

Asset	Patent strength	Reason
Acetaminophen alone	Low	Long-established generic active
Ibuprofen alone	Low	Long-established generic active
Basic fixed-dose combination	Low to moderate	Combination is commercially useful but may be obvious
Conventional coated caplet	Low	Standard excipient and process architecture
Bilayer tablet	Moderate	Can support structural and process claims
Rapid-dissolution formulation	Moderate	Strength depends on comparative data
Softgel or liquid-filled capsule	Moderate	Different vehicle and manufacturing platform
Stabilized amorphous ibuprofen	Moderate to high	Stronger if stability and performance are unexpected
Extended-release combination	Moderate to high	Requires substantial formulation and regulatory work
Packaging system	Low to moderate	Useful as a secondary barrier, rarely a standalone moat
Manufacturing know-how	Moderate	Trade secrets can be important even without broad patents

The strongest strategy is usually a layered estate. It should combine composition claims, dosage-form claims, process claims, stability claims, and packaging claims. A single broad claim covering "acetaminophen and ibuprofen for back pain" is unlikely to provide durable protection.

What FDA regulatory pathway applies to the combination?

A new product must fit the applicable OTC monograph framework or proceed through an FDA application. The FDA’s internal analgesic, antipyretic, and antirheumatic monograph covers established OTC ingredients and permitted conditions of use.[3]

Regulatory issues include:

• Active-ingredient amounts and daily dosing.
• Required warnings for acetaminophen.
• NSAID gastrointestinal, cardiovascular, renal, and allergic-reaction warnings.
• Labeling against duplicate acetaminophen or NSAID use.
• Dose frequency and maximum daily use.
• Claims for backache, muscle ache, arthritis pain, and other minor pain.
• Stability and dissolution specifications.
• Packaging requirements, including child-resistant packaging where applicable.
• Manufacturing compliance under current good manufacturing practice.

Acetaminophen labeling must address severe liver damage risk from excessive dosing or concurrent use of multiple acetaminophen-containing products.[4] Ibuprofen labeling must address gastrointestinal bleeding, cardiovascular risk, kidney risk, and hypersensitivity concerns associated with NSAIDs.[5]

A back-pain product should avoid implying treatment of serious or chronic pathology. OTC labeling is better aligned with temporary relief of minor aches and pains than with claims to treat nerve compression, inflammatory spinal disease, or structural back disorders.

Which companies are challenging the branded market?

The competitive field includes four groups:

1. Branded consumer-health companies, including Haleon.
2. Retailer-owned private-label manufacturers.
3. Generic drug manufacturers.
4. Novel OTC formulation developers.

Private-label competition is especially strong because the active ingredients are inexpensive and the dosage form is familiar. Retailers can compete through lower pricing, larger count sizes, club packs, and digital search placement.

A challenger gains more leverage by offering a clear product-level advantage:

• Smaller caplet.
• Easier-to-swallow coating.
• Faster dissolution.
• Lower ibuprofen exposure.
• Single-dose blister packaging.
• A liquid or softgel format.
• A differentiated combination ratio.
• A compliance-oriented package that reduces duplicate dosing.

Without one of these advantages, the market is likely to compete primarily on price and brand visibility.

What commercial opportunities exist for excipient-led products?

Premium immediate-release caplet

A premium caplet can use a compact formulation, high-performance disintegrant system, improved coating, and unit-dose blister. The opportunity is strongest in pharmacies and e-commerce, where consumers search for combined pain relief and backache products.

Softgel or liquid-filled capsule

A softgel can differentiate through swallowability, perceived onset, and a distinct consumer experience. It may command a premium over a standard tablet but requires stronger manufacturing controls and more expensive packaging.

Bilayer tablet

A bilayer product can support a formulation patent and provide a credible technical narrative around separate optimization of the two actives. It is most attractive where the manufacturer has robust multilayer compression capabilities.

Travel and workplace packaging

Back pain is episodic and often managed outside the home. Small blister packs, single-day pouches, and tamper-evident travel formats can support higher margins than bulk bottles. Packaging claims must remain consistent with FDA requirements and avoid encouraging unsafe repeated use.

Private-label licensing

A formulation owner can license a protected tablet, softgel, or packaging platform to pharmacy chains, mass retailers, and regional brands. Licensing terms could include:

• Upfront formulation fee.
• Per-unit royalty.
• Territory restrictions.
• Channel exclusivity.
• Minimum annual purchase commitments.
• Manufacturing technology transfer.
• Trademark or co-brand rights.

The most defensible licensing asset is a formulation with demonstrated manufacturing or stability advantages, not a generic fixed-dose concept.

What patent litigation and settlement risks exist?

Paragraph IV litigation risk is lower than in high-value prescription products because the ingredients are generic and OTC competitors may enter through monograph compliance rather than an ANDA challenge. Litigation risk can still arise from:

• A patented bilayer or softgel formulation.
• A specific dissolution profile.
• A manufacturing process.
• Trade dress or trademark claims.
• False advertising involving onset, superiority, or duration.
• Misappropriation of manufacturing know-how.

A settlement agreement could delay entry if a challenger has filed an ANDA against an NDA-listed product, but that analysis depends on the specific NDA, patent listings, certification, and litigation record. The broad acetaminophen/ibuprofen back-pain category does not, by itself, establish a known Paragraph IV barrier.

How does acetaminophen/ibuprofen compare with competing back-pain products?

Product category	Main advantage	Main limitation	Patent opportunity
Acetaminophen alone	Familiarity and broad availability	No anti-inflammatory NSAID activity	Minimal
Ibuprofen alone	Anti-inflammatory positioning	NSAID warnings and tolerability limits	Minimal
Acetaminophen/ibuprofen combination	Two-mechanism analgesia in one unit	Duplicate-use and safety complexity	Moderate only with formulation innovation
Naproxen products	Longer dosing interval	Longer NSAID exposure and safety considerations	Limited for basic products
Topical NSAIDs	Lower systemic exposure potential	Localized application and penetration limits	Higher in delivery systems
Heat wraps and patches	Non-drug positioning	Variable relief and limited drug effect	Moderate in device or delivery technology
Prescription muscle relaxants or opioids	Different clinical use	Prescription controls and safety liabilities	Not direct OTC substitutes

The combination is commercially strongest as a convenience product for short-term minor backache. It should not be positioned as interchangeable with products intended for chronic, neuropathic, severe, or medically diagnosed back pain.

What generic launch risks exist?

A conventional product faces relatively low technical entry barriers. The main launch risks are commercial and regulatory:

• Active-ingredient supply qualification.
• Dissolution failure caused by ibuprofen variability.
• Tablet sticking or coating defects.
• Acetaminophen degradation during storage.
• Labeling errors involving duplicate ingredients.
• Packaging failures under heat and humidity.
• Inconsistent tablet appearance.
• Consumer confusion over total daily doses.
• Retailer margin pressure.
• Advertising claims that exceed the OTC label.

A technically differentiated formulation can raise entry costs, but a competitor may design around the formulation with a different excipient system, dosage form, or manufacturing process.

What geographic coverage and manufacturing barriers matter?

The U.S. is a large but price-sensitive OTC market. Europe, Canada, Australia, and Asian markets have different rules for combination analgesics, permitted doses, package sizes, and advertising claims. Some jurisdictions regulate acetaminophen under the name paracetamol and apply different combination-product standards.

Manufacturing barriers are usually moderate:

• High-speed tablet compression is widely available.
• Film coating is standard technology.
• Softgel manufacturing is more specialized.
• Bilayer compression requires dedicated equipment and process controls.
• Amorphous or nano-sized ibuprofen may require specialized material handling.
• High-barrier packaging can raise cost but is broadly accessible.

The strongest manufacturing moat comes from a reproducible process that delivers consistent dissolution, low defect rates, and long shelf life at commercial scale.

Key Takeaways

• Acetaminophen and ibuprofen for back pain is an OTC fixed-dose combination category, represented in the U.S. by Advil Dual Action.
• The active ingredients are generic and do not provide meaningful composition-of-matter exclusivity.
• A conventional coated caplet has limited patent strength.
• Bilayer tablets, softgels, rapid-dissolution systems, stabilized ibuprofen, and extended-release formats offer stronger formulation opportunities.
• Excipient selection should focus on ibuprofen wetting, rapid disintegration, stability, tablet size, coating performance, and consumer tolerability.
• FDA labeling must control acetaminophen overdose risk and NSAID-related gastrointestinal, cardiovascular, renal, and hypersensitivity risks.
• Commercial differentiation is more likely to come from dosage form, packaging, brand, and retail execution than from the basic analgesic combination.
• Generic entry risk is high for standard tablets and lower for technically differentiated formulations with enforceable claims.
• A layered patent and trade-secret strategy is preferable to a single broad combination claim.
• Licensing opportunities are strongest for scalable softgel, bilayer, rapid-release, or stability-enhanced platforms.

FAQs

Can acetaminophen and ibuprofen be combined in one tablet for back pain?

Yes. Fixed-dose combination products can contain both active ingredients, provided the formulation and labeling comply with applicable FDA requirements. The product must include warnings against exceeding acetaminophen limits or combining multiple acetaminophen- or NSAID-containing products.

Is a liquid-filled acetaminophen/ibuprofen capsule commercially attractive?

Yes. A liquid-filled capsule can offer swallowability and formulation differentiation, but it requires control of precipitation, shell compatibility, fill stability, and manufacturing cost.

Can a manufacturer patent acetaminophen and ibuprofen for backache?

A broad use claim is unlikely to provide strong protection because both ingredients and the analgesic use are established. Patent value is more likely in a specific formulation, release profile, manufacturing process, or stability improvement.

Does a back-pain indication create a separate exclusivity period?

No. A backache claim on an OTC analgesic does not independently create meaningful exclusivity when the active ingredients and general pain-relief use are already established.

What is the best excipient opportunity for a low-cost generic?

A robust immediate-release system using a high-performance disintegrant, optimized wetting, controlled lubrication, efficient film coating, and moisture-protective packaging offers the best balance of cost, manufacturability, and product performance.

References

1. DailyMed. (n.d.). Advil Dual Action: Acetaminophen and ibuprofen tablet, film coated. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products.
4. U.S. Food and Drug Administration. (2023). Acetaminophen information.
5. U.S. Food and Drug Administration. (2023). Nonsteroidal anti-inflammatory drugs: Drug safety communication and labeling information.